Cervical CancerADSNCT02280642
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
An observational study of Cervical Cancer and Genital Warts, run by Duke University at 3 sites in United States.
Trial summary
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as measured one month after receipt of a 3rd dose of HPV… Read more about this study
- Who is it for?
- Ages 9 to 18 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cervical Cancer, Genital Warts
- What is being tested?
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time and 2nd dose on time and 3rd dose late
- How many people
- 331 participants
- Where
- 3 sitesUnited States
- Study dates
- Mar 2009to Sep 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 18 years
- Women only
- Healthy volunteers accepted
- Child, Adult
Study population: Adolescent females attending primary care clinics in central North Carolina
Who may be able to join
- A healthy, medically well female between the ages of 9 - 18 years. (Must be between 9 years and younger than 19 years of age) at time of enrollment
- Must be receiving either a 3rd dose of HPV vaccine (All Groups) or a 2nd dose of HPV vaccine (Group 2 only)
- For Group 1 - EITHER 1) The second dose of HPV vaccine must not have been administered and it must be within the specified dosing interval for the second dose of HPV vaccine (> 90 days since the first dose of HPV vaccine) OR 2) The second dose of HPV vaccine must have been administered > 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose of HPV vaccine (> 60 days - < 180 days since the second dose of HPV)
- For Group 2 - The second dose of HPV vaccine must have been administered > 30 days and < 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (> 180 days since the second dose of HPV)
- For Group 3 - The second dose of HPV vaccine must have been administered > 30 days and < 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (> 60 days - < 180 days since the second dose of HPV)
- For Group 4- The second dose of HPV vaccine must have been administered > 90 days after the first dose of HPV of HPV vaccine and it must be within the specified dosing interval for the third dose (> 180 days since the second dose of HPV)
Show all 9Show fewer
- Ability and willingness to participate in the study by providing written informed assent. Verbal assent is acceptable for subjects less than 12 years of age.
- Parent/guardian provides informed consent
- Anticipated ability and willingness to complete all study visits and evaluations
Who cannot join
- Unable to comply with the study protocol
- Receipt of three or more doses of HPV vaccine or receipt of doses of HPV vaccine outside the pre-specified time windows
- Receipt of blood and or blood products (including immunoglobulin) in the past 3 months or anticipated receipt during the study period
- Receipt of a live virus vaccine (varicella virus containing vaccine, any measles, mumps, or rubella virus containing vaccine such as MMR, or yellow fever vaccine but not including live attenuated influenza virus vaccine) within 4 weeks of receipt of the 3rd dose of HPV vaccine or anticipated receipt of a live virus vaccine within 4 weeks after the 3rd dose of HPV vaccine
- History of any physical, mental, or developmental disorder that study personnel believe may hinder a participant's ability to comply with the study requirements
- History of malignancy or confirmed or suspected immunodeficient condition such as HIV infection
Show all 9Show fewer
- Receipt of or history of receipt of any medications or treatments that affect the immune system, such as immune globulin, interferon, immunomodulators, cytotoxic drugs or other drugs known to be frequently associated with significant major organ toxicity since six months prior to the first HPV vaccine dose. Receipt of long-term (greater than or equal to 2 weeks) potentially immunosuppressive corticosteroid use within six months prior to HPV vaccine dose 1 and enrollment or anticipated receipt during the study period. Specifically, potentially immunosuppressive corticosteroids are any parenteral corticosteroid, high dose (>800 mcg/day) beclomethasone dipropionate or equivalent medication. Nasal and topical steroids are allowed.
- Current or former participation in HPV vaccine related research.
- Receipt of an investigational or alternate HPV vaccine
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Chapel Hill Pediatrics
Chapel Hill, North Carolina, 27514
Duke Children's Primary Care
Durham, North Carolina, 27704
Durham Pediatrics
Durham, North Carolina, 27704
About this study
Official title: Alternate Dosing Schedules Study for HPV Vaccine
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as measured one month after receipt of a 3rd dose of HPV vaccine) when compared to vaccine delivered according to the recommended dosing schedule.
This was a prospective observational study of healthy 9-18 year old female patients receiving either a second or third dose of HPV vaccine as part of their well child care. Immune responses to HPV types 6, 11, 16 and 18 were measured both before and 1 month after the third dose of HPV vaccine with the purpose of comparing the immune responses to HPV vaccine when administered at naturally occurring longer dosing intervals to the immune response to HPV vaccine when administered as routinely recommended.
Read more
In addition, girls receiving a 3rd dose of HPV vaccine as well as concomitantly administered vaccines by injection were randomized to receive either the HPV vaccine first or their concomitantly administered vaccines first. Pain following vaccination was assessed in each arm using the Faces Pain Scale - Revised.
Please note: This record refers only to the observational portion of the study. Please refer to NCT00862810 for the results of the randomized portion of the study.
- Conditions
- Cervical Cancer, Genital Warts
- Being tested
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late
- Keywords
- Human papillomavirus, Cervical cancer, Genital warts, Vaccine, Immunogenicity
- Medical subject headings
- Uterine Cervical Neoplasms, Condylomata Acuminata
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Both 2nd and 3rd doses on timeBiological
2nd dose late and 3rd dose on timeBiological
2nd dose on time and 3rd dose lateBiological
Both doses lateBiological
| Study group | Role | What they receive |
|---|---|---|
| Both doses on time | An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2. Receives: Biological: Both 2nd and 3rd doses on time | |
| Dose 2 delayed | A delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2. Receives: Biological: 2nd dose late and 3rd dose on time | |
| Dose 3 delayed | An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2. Receives: Biological: 2nd dose on time and 3rd dose late | |
| Both doses delayed | A delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2. Receives: Biological: Both doses late |
What is being measured
The primary outcome is the main question the study is designed to answer.
HPV 6 GMT
Geometric mean titer (GMT) of antibody to HPV type 6
Measured: 1 month following 3rd dose of HPV vaccine
HPV 11 GMT
Geometric mean titer (GMT) of antibody to HPV type 11
Measured: 1 month following 3rd dose of HPV vaccine
HPV 16 GMT
Geometric mean titer (GMT) of antibody to HPV type 16
Measured: 1 month following 3rd dose of HPV vaccine
HPV 18 GMT
Geometric mean titer (GMT) of antibody to HPV type 18
Measured: 1 month following 3rd dose of HPV vaccine
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2014 (estimated)
- Study startMar 2009
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical CancerStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 331 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- Responsible party
- Sponsor
- Investigators
- Emmanuel B Walter, MD, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02280642
- Sponsor's protocol ID
- Pro00014388_1
- Other IDs
- CDC#U36/CCU319276 CFDA 93.283
- Acronym
- ADS
- Status last verified
- Oct 2014
- First submitted
- 29 Oct 2014
- Last updated
- 31 Oct 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Alternate Dosing Schedules Study for HPV Vaccine
- ClinicalTrials.gov ID
- NCT02280642
- Acronym / sponsor ID
- ADS / Pro00014388_1
- Conditions
- Cervical Cancer, Genital Warts
- Keywords
- Human papillomavirus, Cervical cancer, Genital warts, Vaccine, Immunogenicity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 331 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- Study start
- Mar 2009
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 31 Oct 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as measured one month after receipt of a 3rd dose of HPV vaccine) when compared to vaccine delivered according to the recommended dosing schedule.
This was a prospective observational study of healthy 9-18 year old female patients receiving either a second or third dose of HPV vaccine as part of their well child care. Immune responses to HPV types 6, 11, 16 and 18 were measured both before and 1 month after the third dose of HPV vaccine with the purpose of comparing the immune responses to HPV vaccine when administered at naturally occurring longer dosing intervals to the immune response to HPV vaccine when administered as routinely recommended.
In addition, girls receiving a 3rd dose of HPV vaccine as well as concomitantly administered vaccines by injection were randomized to receive either the HPV vaccine first or their concomitantly administered vaccines first. Pain following vaccination was assessed in each arm using the Faces Pain Scale - Revised.
Please note: This record refers only to the observational portion of the study. Please refer to NCT00862810 for the results of the randomized portion of the study.
Study design
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Both doses on time | – | Biological: Both 2nd and 3rd doses on timeAn on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2. |
| Dose 2 delayed | – | Biological: 2nd dose late and 3rd dose on timeA delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2. |
| Dose 3 delayed | – | Biological: 2nd dose on time and 3rd dose lateAn on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2. |
| Both doses delayed | – | Biological: Both doses lateA delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2. |
Who may qualify
- Ages
- 9 to 18 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Adolescent females attending primary care clinics in central North Carolina
Key inclusion criteria (9 listed)
- A healthy, medically well female between the ages of 9 - 18 years. (Must be between 9 years and younger than 19 years of age) at time of enrollment
- Must be receiving either a 3rd dose of HPV vaccine (All Groups) or a 2nd dose of HPV vaccine (Group 2 only)
- Ability and willingness to participate in the study by providing written informed assent. Verbal assent is acceptable for subjects less than 12 years of age.
- Parent/guardian provides informed consent
- Anticipated ability and willingness to complete all study visits and evaluations
Key exclusion criteria (9 listed)
- Unable to comply with the study protocol
- Receipt of three or more doses of HPV vaccine or receipt of doses of HPV vaccine outside the pre-specified time windows
- Receipt of blood and or blood products (including immunoglobulin) in the past 3 months or anticipated receipt during the study period
- Receipt of a live virus vaccine (varicella virus containing vaccine, any measles, mumps, or rubella virus containing vaccine such as MMR, or yellow fever vaccine but not including live attenuated influenza virus vaccine) within 4 weeks of receipt of the 3rd dose of HPV vaccine or anticipated receipt of a live virus vaccine within 4 weeks after the 3rd dose of HPV vaccine
- History of any physical, mental, or developmental disorder that study personnel believe may hinder a participant's ability to comply with the study requirements
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Both 2nd and 3rd doses on time | Biological | Both doses on time |
| 2nd dose late and 3rd dose on time | Biological | Dose 2 delayed |
| 2nd dose on time and 3rd dose late | Biological | Dose 3 delayed |
| Both doses late | Biological | Both doses delayed |
Primary outcome
HPV 6 GMT
Time frame: 1 month following 3rd dose of HPV vaccine
Geometric mean titer (GMT) of antibody to HPV type 6
HPV 11 GMT
Time frame: 1 month following 3rd dose of HPV vaccine
Geometric mean titer (GMT) of antibody to HPV type 11
HPV 16 GMT
Time frame: 1 month following 3rd dose of HPV vaccine
Geometric mean titer (GMT) of antibody to HPV type 16
HPV 18 GMT
Time frame: 1 month following 3rd dose of HPV vaccine
Geometric mean titer (GMT) of antibody to HPV type 18
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2014.
Related trials for Cervical Cancer
Recruiting
Feasibility of Cough Skill Training in Individuals With Head and Neck Cancer
Head and Neck Cancers
RecruitingPhase 1/2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Colorectal Cancer
Recruiting
The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of Swallowing Function and Quality of Life
Nasopharyngeal Carcinoma (NPC)
Enrolling by invitationObservational study
Head and Neck Cancer Strategies
Head and Neck Cancer (H&N), Thyroid Cancer
Active, not recruiting
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection
Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emmanuel B Walter, MD principal investigator
Duke University
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cervical Cancer and Genital Warts, run by Duke University at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HPV 6 GMT (time frame: 1 month following 3rd dose of HPV vaccine). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2014.